CervoMed (NASDAQ:CRVO – Get Free Report) had its price objective raised by analysts at Roth Mkm from $7.00 to $15.00 in a research note issued on Tuesday, Benzinga reports. The firm presently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback